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MicroRNAs (miRNAs) directly regulate gene expression at a post-transcriptional level and represent an attractive therapeutic target for awide range
of diseases. Here, we report a novel strategy for delivering miRNAs to endothelial cells (ECs) to regulate angiogenesis, using polymer functionalized
carbon nanotubes (CNTs). CNTs were coated with two different polymers, polyethyleneimine (PEI) or polyamidoamine dendrimer (PAMAM),
followed by conjugation ofmiR-503 oligonucleotides as recognized regulators of angiogenesis.We demonstrated a reduced toxicity for both polymer-
coatedCNTs, comparedwith pristineCNTs or polymers alone.Moreover, polymer-coatedCNT stabilizedmiR-503 oligonucleotides and allowed their
efficient delivery to ECs. The functionality of PAMAM-CNT-miR-503 complexeswas further demonstrated in ECs through regulation of target genes,
cell proliferation and angiogenic sprouting and in a mouse model of angiogenesis. This comprehensive series of experiments demonstrates that the use
of polyamine-functionalized CNTs to deliver miRNAs is a novel and effective means to regulate angiogenesis.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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coated carbon nanotu.... Nanomedicine: NBM 2016;12:1511-1522, http://dx.doand cardiovascular disease has recently attracted considerable
research interest.1,2 Recent studies have revealed important roles
for miRNAs in regulating angiogenesis, particularly via regulation
of endothelial cell (EC) function.3
The term angiogenesis is used to generally indicate the
growth and remodeling process of the primitive vascular network
into a complex network during pre-natal development. After
birth, reparative angiogenesis is activated during wound healing
and in response to vascular injury, while pathological angiogen-
esis contributes to tumor growth and pulmonary hypertension.
While it is desirable to block the growth of new blood vessels under
these circumstances, the controlled stimulation of angiogenesis is
beneficial when the local blood supply is impaired.4
Since adaptation and remodeling of vasculature also involve
epigenetic components such as microRNAs, the modulation of
their expression through innovative technologies would repre-
sent a way to regulate the expression of multiple genes, thus
opening new avenues for vascular therapeutics. Regulation of
member of miR-16 family, including miR-503, controls EC
function and angiogenesis in different murine models of vascular
disease (reviewed in5). We have previously shown that localarticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
he efficient delivery of microRNAs into endothelial cells using polyamine-
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diabetic mice.6 Finally, miR-503 is also involved in regulation of
EC proliferation during development of pulmonary hyperten-
sion. Lung delivery of miR-503 mimics inhibits pulmonary
artery EC proliferation and could alleviate PAH pathogenesis.7
Although miRNA-based therapeutic interventions are being
considered, they are currently underdeveloped for a range of clinical
cardiovascular applications.8
The major challenge of miRNA-based therapies is an existing
need to increase the delivery and stability of miRNA regulators,
while minimising off-target effects.9 Naked miRNA mimics or
anti-miRNAs are highly charged and often unstable in the
circulation; thus development of suitable carriers represents an
attractive means to target delivery to diseased areas.10 Moreover,
cell interaction in the presence of serum proteins is a limiting
factor for many nanotechnology approaches to RNA delivery.11
Several strategies have been reported for the delivery of
miRNAs, including liposomes,12 biodegradable chitosans13 and
adeno-associated virus or lentivirus.14 In recent years, much
effort has been made in developing non-viral vector systems for
gene therapy.11 These systems could provide better biocompati-
bility and lower toxicity in comparison with the viral carriers, as
well as development for a large-scale production. The advent of
nanotechnology (development of materials with at least one
dimension of b100 nm) has the potential to revolutionize many
forms of industry, and offers novel possibilities for biomedical
applications and drug delivery.15 A variety of nanoparticles constructed
from lipids, polymers and metals have already been evaluated as
delivery systems for siRNAs,16 and similar conceptual frameworks
have been applied to miRNA mimics and anti-miRNAs.17,18
Carbon nanotubes (CNTs) have recently gained high
popularity as potential drug carriers, therapeutic agents and
diagnostic tools.19 CNTs are one dimensional cylindrical
graphene sheets, either as a single-wall (single wall carbon
nanotube; SWNTs) or multiple coaxial walls (multi-walled
carbon nanotubes; MWNTs). Due to their hydrophobic surfaces,
unmodified (‘pristine’) CNTs are not soluble in aqueous
solutions and readily agglomerate into large particle clusters.
Surface functionalization is required to suspend CNTs in a way
that minimises agglomeration and renders them biocompatible
for their medical applications.20 Furthermore, use of cationic
molecules or polymers, such as polyethyleneimine (PEI) or
polyamidoamine dendrimer (PAMAM), to improve CNTs
functional properties leads to their electrostatic interaction with
the negatively charged siRNAs or plasmid DNA, thus increasing
nucleic acid loading on nanomaterials.21,22 Finally, functiona-
lization of CNTs may also facilitate their entry into the cells by
endocytosis or by penetrating directly through cell membranes,
thus transporting molecules of interest across the cytoplasmic
and nuclear membranes without toxicity.23,24 Nano-formulations
based on functionalized CNTs have successfully been used to
deliver siRNA in in vitro and in vivo models.25
In this study, pristine CNTs were functionalized with a high
molecular weight branched PEI or PAMAM to develop two
effective delivery systems for transferring miR-503 oligonucle-
otides into ECs. We demonstrate that ECs can rapidly internalize
the miR-503-carrying CNTs and that polymer-coated CNTs
exhibit lower toxicity than the pristine CNTs or pure polymers.In particular, CNTs coated with PAMAM show better
transfection efficiency compared with the PEI-CNT formulation.
Most importantly, we demonstrate that PAMAM-coated
CNTs increase the stability of miR-503 oligonucleotides and,
consequently, regulate target gene expression and angiogenesis
in vivo.Methods
A detailed version of the Methods is available as Supple-
mentary Materials.Results
Preparation of polyamine-coated CNTs
Polyamine-coated CNTs were prepared by overnight incuba-
tion of pristine CNTs in the presence of PEI polymer (PEI-CNTs)
or PAMAM dendrimer (PAMAM-CNTs) (Figure 1, A). The
polymer/dendrimer adsorption onto CNTs occurs spontaneously,
likely through hydrophobic interactions, although the precise
physicochemical mechanism and molecular interactions still
remain to be defined. To evaluate the amount of PEI or
PAMAM polymer bound to CNTs, we exploited the colorimetric
reaction of ninhydrin26 whereby free amine groups of unbound
polymer can be monitored by spectrophotometry. The amount of
PEI (or PAMAM) bound to CNTs was modest (4.2 ± 0.1% of the
starting polymer amount for both compounds, which correspond to
a final polymer/CNTs weight ratio of 1:10) but sufficient to
allow further complex formation with oligonucleotides. Thermal
analysis (TGA) performed on PEI-CNTs and PAMAM-CNTs
(Figure 1, B) confirmed that the weight loss of these two
compounds is ~12%-14% at a temperature where the weight loss
of the pristine CNTs is approximately 4%-5%.
Physicochemical characterization of polyamine-coated CNTs
Transmission electron microscopy (TEM) of polyamine-
coated CNT suspensions did not show significant differences
between the pristine and the polymer-coated CNTs (Figure 1, C).
Themajority of CNTs had a length between 200 nm and 1200 nm,
with a median length of 652 nm (interquartile range:
332-1098 nm; N = 33; Figure 1, D). High resolution
TEMs images showed two groups of CNTs which in terms of
width (diameter) varied from either ~13-14 nm or 26-58 nm
(Figure 1, D). These values are in broad agreement with the
concentric layer morphology of multi-walled CNTs and the
nominal diameter of the original material (20-40 nm). Dynamic
light scattering did not display differences between the dimensions
of individual nanotubes with or without PEI or PAMAM grafting,
suggesting that the coating with these polymers did not alter the
dimension of CNTs in the experimental conditions employed (data
not shown). The ζ-potential of diluted suspensions of PEI-CNTs
andPAMAM-CNTs indicated positively charged values (11.7 ± 1.9
and 18.9 ± 1.8 mV, respectively) and strongly suggested that these
compounds can bind nucleic acids.
Figure 1. Polymer coating anddimensions of carbon nanotubes. (A)Schematic representation of polymer-coated (PEI andPAMAM)CNTpreparation.Boxes report only
a part of the PEI and PAMAM molecular structure. (B) Thermal analysis (TGA) performed on pristine CNTs, PEI-CNTs and PAMAM-CNTs. (C) Representative
transmission electronmicroscopy (TEM) images of individualCNTs.Main panel showing inherent differences inCNT length andwidth,with small panels showinghigher
magnification of each type of CNT (scale bar = 200 nm). (D) Length and width of pristine CNTs derived from TEM images. Box and whisker plots with central bar
indicating median value, box indicating interquartile range, and whiskers 10%-90% range (length: N = 33 from n = 5 subsamples; width: N = 6 from high resolution
images of n = 3 subsamples). (E)Agarose gel (1%) stainedwithHoechst 33258 showing that PEI-coated CNTs are able to bindDNA (5:1w/w) (lanes 4 and 8) compared
to uncoated/pristine CNTs (lanes 3 and 7). DNA ladder (50 bp) was loaded in lanes 1 and 5, fragmentedDNA (b50 bp) in lane 2 and a well-characterized DNA fragment
(~250 bp) in lane 6.
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To assess the ability of polyamine-coated CNTs to bind
oligonucleotides, we performed agarose gel retardation assays
(Figure 1, E). Polyamine-coated CNTs were able to bind
efficiently both small DNA fragments (b50 nt) (similar to
miRNA-mimics) and longer fragments (~250 bp) by forming
large polyplexes that are unable to migrate through the gel
(Figure 1, E, lanes 4 and 8). Uncoated CNTs did not form
complexes with DNA under these experimental conditions
(Figure 1, E, lanes 3 and 7) or migrate through the gel.
PAMAM-CNTs displayed similar DNA binding properties
(data not shown). Thus, despite relatively low levels of polymer
bound to CNTs, polyamine-coated CNTs were still able to bind
DNA efficiently.
Cytotoxicity of polyamine-coated CNTs
Human umbilical vein endothelial cells (HUVECs) were
treated with PEI-CNTs or PAMAM-CNTs (10-50 μg/mL) and
cytotoxicity measurements are given in Figure 2, A. Viability of
HUVECs decreased with increasing concentrations of PEI-CNTs
or PAMAM-CNTs, with low levels of cytotoxicity occurring at
concentrations above 20 μg/mL (Figure 2, A). Interestingly, at
the highest concentration tested, both polyamine-coated CNTs
showed reduced cell toxicity compared with pristine CNTs
(Figure 2, A). In particular, PAMAM-CNTs exhibited a lower
toxicity compared with PEI-CNTs or pristine CNTs. Cell toxicity
of polymer coated-CNTs was also compared with the equivalent
concentration of unbound polymer (i.e. without CNTs).
Surprisingly, unbound polymers were relatively toxic at low
concentrations (1 μg/mL; equivalent concentration to 10 μg/mL
polyamine-bound CNTs). At a dose of 5 μg/ml (equivalent to
50 μg/mL polyamine-CNTs), less than 20% or 60% of cells were
viable in the presence of PEI or PAMAM respectively, while
70% or 90% of cells were viable when incubated with PEI-CNTs
or PAMAM-CNTs, respectively (Figure 2, B). As reported in
other studies in different cell lines,22,27 these results show that
polymers coated with CNTs were less cytotoxic to HUVECs
cells compared to polymer only or pristine CNTs.
Free radical generation by pristine and polyamine-coated CNTs
Generation of cellular oxidative stress through free radical
generation is a consistently proposed mechanism for the toxicity
of nanoparticles.28 Incubation of pristine or polymer-coated
CNTs indicated that pristine or polyamine-coated nanotubes
generated EPR-detectable free radicals in physiological buffer
(Figure 2, C). Free radical production after 60 min incubation
was linear over time (data not shown), and significantly
increased as a function of the concentration of nanotubes
(Figure 2, D). Pristine CNTs generated significantly more free
radicals than either the PEI- or PAMAM-CNTs indicating that
polymer-coating has a favorable anti-radical effect. The assay
confirmed that pristine CNTs were able to induce significant
levels of reactive oxygen species (ROS) production in HUVECs
in a dose-dependent manner. As with innate CNT-derived free
radicals, polymer-coated CNTs produced a lower level of ROS,
especially PAMAM-coated CNTs (Figure 2, E).Regulation of endothelial permeability by CNTs
The alteration of vascular permeability has been suggested to
have a crucial role not only in the pathogenesis of several
diseases (i.e. cardiovascular diseases, diabetes, insulin resistance,
chronic kidney failure, and tumors),29 but also on drug delivery
to cells, tissues, and organs.30 We then investigated whether
exposure of ECs to nanotubes led to changes in EC barrier
function using electric cell substrate impedance sensing
(ECIS).31 ECs treated with pristine CNTs displayed a significant
decrease in impedance compared with control cells, indicating an
increase in cell monolayer permeability (Figure 2, F). Significant
changes were seen at the lowest concentration (10 μg/mL) of
pristine CNTs, whereas polymer-coated CNTs increased cell
monolayer permeability only at the high dose.
Delivery of miRNAs in endothelial cells by
polyamine-coated CNTs
In order to verify the delivery efficiency of polymer-coated
CNTs to HUVECs, PEI-CNTs and PAMAM-CNTs were
complexed with Cy3-labelled oligonucleotides as a quantifiable
surrogate for miRNA precursor (pre-miRNA) or miRNA
inhibitor (anti-miRNA) and quantified by flow cytometry
(FACS) after 24 h (Figure 3, A). At 5:1 weight ratio
polyamine-CNTs/pre-miRNA or polyamine-CNTs/anti-miRNA,
51% vs 32% of HUVECs were labelled with PEI-CNTs and
PAMAM-CNTs, respectively. At 10:1 weight ratio 89% of
HUVECs were labelled with PEI-CNTs, whereas PAMAM
coating increased the transfection efficacy to 99%. PAMAM-coated
CNTswere able to deliver anti-miRmore efficiently than PEI-coated
CNTs (Figure 3, A).
We have then investigated the kinetic of the uptake of
Cy3-labelled oligonucleotides complexed with CNTs in
HUVECs. We used PAMAM or PEI CNT/pre-miR complex
(10:1 w/w) and we followed the cellular uptake by FACS for
48 h. Already after 4 hr, labelled-CNTs are detected inside the
60% of the cells, while at 24 hr the majority of the cells
displayed the Cy3-labelled CNTs (Figure 3, B).
To confirm the intracellular localization of CNTs/pre-miRNA
complex, we observed HUVECs by transmission electron
microscopy (TEM) (Figure 3, C). TEM images did not show
any visible evidence of cytotoxicity or cell activation in
HUVECs treated with CNTs/pre-miRNA (w/w 10:1). Following
24 h incubation of HUVECs, CNTs were visible adhering to the
cell surface and, importantly, inside cells (Figure 3, C (i)). The
CNTs were observed in the cell cytoplasm but not within cell
nuclei. In some cases the CNTs appeared to be distributed freely
in cell cytoplasm (Figure 3, C (ii)), whereas often they were
visible as aggregates within vacuoles (Figure 3, C (iii) & (iv)).
Functional miR-503 is delivered to endothelial cells by
polymer-coated CNTs
qPCR of miR-503 expression was used to confirm that
polyamine-coated CNTs can be used as efficient miRNA delivery
systems, using both anti- and pre-miR-503 oligonucleotide-bound
CNTs, in comparison with that of the commercial transfection
agent RNAiMAX Lipofectamine. Both polyamine-CNTs
Figure 2. In vitro evaluation of toxicity, ROS production and EC permeability by polyamine-CNTs. Cell viability of (A) PEI and PAMAM-coated CNTs or (B)
in comparison with unbound PEI and PAMAM was determined by MTT assay and expressed as the percentage of the optical density at 570 nm of treated cells
relative to vehicle. Mean ± SEM (n = 5), *P b 0.05, **P b 0.01 vs NT. (C) Representative electron paramagnetic resonance (EPR) spectra from reaction of
Tempone-H with superoxide generated from pristine CNTs. The amplitude of peaks indicates the magnitude of free radical production. (D) Superoxide free
radical generation from CNTs in the absence of cells, quantified by EPR. Pristine CNTs (black) generated significantly more superoxide than PEI-coated CNTs
(blue) or PAMAM-coated CNTs (red). Pyrogallol (grey; 30 μmol/L) was used as positive control for generation of superoxide. Mean ± SEM (n = 5 for CNTs,
n = 7 for pyrogallol). *P b 0.05 compared to pristine CNT, one-way ANOVA with Tukey's post-hoc test. (E) Total ROS production from HUVECs treated
with CNTs. Equivalent DMSO-treated cells have been used as control. Mean ± SEM (n = 5), *P b 0.05 or **P b 0.01 vs DMSO. (F) Effect of CNTs on the
permeability of the endothelial monolayer evaluated using an electric cell substrate impedance sensing (ECIS) system. Mean ± SEM (n = 3), *P b 0.05 or
**P b 0.01 vs untreated cells.
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cells, as demonstrated by the regulation of levels of miR-503
detected in HUVECs. PAMAM-CNTs showed miRNA oligonu-
cleotide delivery efficiency similar to the commercial transfection
agent (Figure 4, A and B). We have previously demonstrated thatover-expression of miR-503 in vitro and in vivo considerably
decreases cell proliferation target CDC25A.6 Loaded-CNTs
regulated CDC25A mRNA levels in accordance with their ability
to change miR-503 expression (Figure 4, C and D), whereas this
effect was not observed in cell transfected with scramble sequence
Figure 3. Polyamine-coated CNTs deliver miRNA to endothelial cells.PEI-CNTs and PAMAM-CNTs (10-50 μg/mL) were complexed with pre- or anti-miRNA
(50 nM) Cy3-labelled oligonucleotides and incubated with HUVECs. (A) Flow cytometry analysis of HUVECs treated with CNTs complexed with pre- or
anti-miRNA or transfected with Lipofectamine. Efficiency of transfection is expressed as percentage of Cy3-positive cells. Mean ± SEM (n = 5). (B) Time
course of the uptake of CNT-miR-Cy3 in HUVECs. Mean ± SEM (n = 5) (C) Representative transmission electron microscopy images showing penetration of
PAMAM-CNTs/pre-miRNA (10:1 w/w) into endothelial cells at 48 h. EC = endothelial cell, ECN = endothelial cell nucleus. Arrow heads in (i) show carbon
nanotubes. Arrows in (iii) & (iv) show membrane of vacuole surrounding CNTs.
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transfection shown by PAMAM-CNTs (Figure 4, A), these
dendrimer-coated CNTs are more effective in regulating
CDC25A expression than PEI-CNTs. Overall, our results show
that polymer-coated CNTs allow the translocation of miR-503 into
HUVECs and thatmiRNA is efficiently released fromCNT-complexes
and remains functionally active.In vitro activity of CNT-miR-503 formulations in
endothelial cells
The biological consequences of miR-503 oligonucleotides
delivered by polyamide-coated CNTs were assessed by moni-
toring EC proliferation using BrdU and EC migration.
Pre-miR-503 strongly decreased HUVEC proliferation, whereas
anti-miR-503 exerted the opposite effect. In agreement with the
level of expression of CDC25A, PAMAM-CNTs show a
stronger effect on HUVEC proliferation than PEI-CNTs
(Figure 5, A). In addition, we have demonstrated that polymer-
coated CNTs conjugated with pre-miR-503 also decrease ECmigration rate while conjugation with anti-miR-503 increases
EC capacity to migrate (Figure 5, B).
To assess the regulation of the ability to form connections by
anti-miR-503/pre-miR-503 complexed with PAMAM-CNTs,
HUVECs were cultured on Matrigel. As expected, cells
transfected with anti-miR-503 yielded vascular networks with
a greater tube length (Figure 5, C i), more branching points
(Figure 5,C ii), and an increased number of meshes (Figure 5,C iii)
and meshes area (Figure 5, C iv) compared to HUVECs transfected
with scrambled sequence miRNA. On the contrary, HUVECs
transfected with pre-miR-503 reduced the majority of these
parameters compared to controls (Figure 5, C).
PAMAM-CNT-miR-503 complex increases miR-503 stability
and angiogenesis in vivo
The delivery of unmodified RNA oligonucleotides in vivo is
greatly limited by their sensitivity to nucleolytic degradation in
serum. Therefore, the stability of polyamine-coated CNTs/miR-503
complexes to RNAse H or serum degradation was analysed further.
As shown in Figure 6, A, pre-miR-503 oligonucleotides conjugated
Figure 4. Polyamide CNTs efficiently deliver miR-503 oligonucleotides.Expression of miR-503 in HUVECs treated with PEI-CNTs or PAMAM-CNTs
conjugated with (A) pre-miR or (B) anti-miR-503 oligonucleotides (10:1 w/w). The commercially available transfection agent Lipofectamine was used as
positive control, and miRNA scramble sequence as negative controls. Expression was normalized to snRU6. Mean ± SEM (n = 5). **P b 0.01 vs
Lipofectamine. Efficiency of delivery assessed by measurement of expression of CDC25A following (C) pre-miR-503 or (D) anti-miR-503 bound to CNTs.
Expression was normalized to 18S. Mean ± SEM (n = 5). *P b 0.05 or **P b 0.01 vs control.
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Similar results have been obtained when polyamine-CNTs/
pre-miR-503 complexes were incubated in serum up to 24 h
(Figure 6, B). However, the unconjugated pre-miR-503 oligonu-
cleotides undergone degradation after 10 min in the presence of
RNAseHor after 4 h in serum.These data supported the evidence that
the conjugation of miRNAs with polyamine-coated CNTs signifi-
cantly stabilized the oligonucleotides against nucleolytic degradation.
We next explore whether PAMAM-CNT-miR-503 formula-
tion reduced microvessels sprouting in a three-dimensional
ex vivo mouse aortic ring angiogenesis assays. In this model,
developing microvessels undergo many key features of angio-
genesis over a timescale similar to that observed in vivo.32 The
numbers of microvessels formed from murine aortic rings
cultured in vitro and scored after 5 days were reduced in the
presence of PAMAM-CNT-pre-miR-503 as compared with
controls (Figure 6, C).
Then, a sponge implant model was used to confirm whether
the PAMAM-CNT formulation improved the stability of miRNA
oligonucleotides and to study their effects on angiogenesis
in vivo. The sponge-induced inflammatory angiogenesis consists
of the implantation of a synthetic polymer in subcutaneous sites in
mice.33 This model allows the quantitation of various components
of the inflammatory angiogenic process and can be used as a
controlled, sustained-release local delivery system for therapeutic
agents.34 Pre-miR-503 oligonucleotides conjugated with
PAMAM-CNTs were incorporated in the sponges and qPCR was
performed using primers that can only detect exogenous miR-503.
After 21 days, only the miR-503 oligonucleotides conjugated with
CNTs were detected in the sponges (Figure 7, A), resulting in thesilencing of its target gene CDC25A (Figure 7, B). Histological
analysis of angiogenesis in the sponges at 21 days by quantification
of VE-cadherin/SM22 vessels (Figure 7,C and E) or CD31/αSMA
(Supplementary Figure 1) demonstrated that the PAMAM-CNT-
pre-miR-503 formulation reduced the number of vessels compared
to sponges containing only control oligonucleotides. The presence
of erythrocytes in the lumen of the vessels indicated that they are
linked to the host-circulation and perfused (Figure 7, E and
Supplementary Figure 2). Delivery of miR-503 by PAMAM-CNTs
does not increase apoptosis in the vessels (Figure 7,C), confirming
that miR-503 affects in vivo angiogenesis through its activity on
proliferation and migration of ECs as previously described.6Discussion
Here we demonstrate that coating of CNTs with PEI or
PAMAM polymers is an effective means to deliver miRNAs into
ECs. Importantly, these compounds exploit their transfection
properties at concentrations that do not determine cytotoxic
effects or loss of EC integrity. We also showed that polymer-
coated CNTs conjugated with pre-miR-503 or anti-miR-503 are
able to regulate cell proliferation and in vitro angiogenesis
through the modification of their target genes. Moreover, the
formulations that we have developed increase the stability of
miRNA oligonucleotides in serum, paving the way for an
effective use of these systems in vivo.
We have employed the polyamine PEI and the dendrimer
PAMAM, two versatile polymers widely used in the past to
obtain several drug delivery vectors for in vitro and in vivo
Figure 5. Delivery of miR-503 by CNTs leads to functional changes in endothelial cell proliferation and tube formation. Effect of CNTs conjugated with pre-miR
or anti-miR-503 oligonucleotides (10:1 w/w) on (A) proliferation (BrdU incorporation assay) and (B)migration of HUVECs. Mean ± SEM (n = 5). *P b 0.05
or **P b 0.01 vs control (scramble sequence oligonucleotides). (C) Effect of pre- or anti-miR-503 delivery by PAMAM-CNTs on HUVECs to assess their
capacity to induce formation of vascular networks. Top panel: representative images of tube-like structure of HUVECs on Matrigel. (Magnification 100×; scale
bar 100 μm). Bottom panel: quantification of i) total length of the tube-like structures, ii) total number of junctions, iii) total number of meshes and iv) total
meshes area by ImageJ software. Mean ± SEM (n = 5). *P b 0.05 or **P b 0.01 vs negative control.
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CNTs consisted in a stable dispersion of CNTs that decreased the
toxicity of pristine nanotubes and limited ROS production,
whereas PEI-CNTs were slightly less effective. Numerous
studies have demonstrated that mammalian cells exposed to
CNTs suffer from oxidative stress through generation of ROS.38
Indeed, CNTs in physiological buffers (in the absence of cells)
generate hydroxyl and superoxide free radicals, the magnitude of
which is dependent on surface area, trace metal contamination
and composition of the buffer used.39 In the present study, we
investigated both innate ROS generation and cellular oxidative
stress. EPR spectroscopy was used to assess ROS generation due
to the high sensitivity of this technique and because measure-
ment is not compounded by the black colour of CNT suspensions
(which generally interferes with other colorimetric assays).Furthermore, we chose the superoxide-selective spin-trap
Tempone-H for the quantification of free radicals, due to the
importance of the scavenging effects of superoxide on nitric
oxide, a key cellular messenger in endothelial cells and
cardiovascular homeostasis. Despite the well-recognized prop-
erty of carbon nanotubes to generate ROS, the functionalization
of CNTs with polyamine or polyamides might also impart to
these nanosystems an additional antioxidant action. Given the
great potential of PAMAM to limit superoxide generation from
pristine nanotubes, further chemical modification of PAMAM-
coated nanotubes, or improved coating efficiency, could actually
inhibit the oxidative damage by ROS production that is a
hallmark of cardiovascular diseases.
There are several potential routes of cellular uptake of CNTs,
the extent of which will depend onmany experimental parameters,
Figure 6. Stability of PAMAM-CNT-miR-503 and effect on ex vivo model of angiogenesis.(A) Kinetics of RNAse H digestion. Values are expressed as
pre-miR-503 expression compared to pre-miR-503 values at time 0. Mean ± SEM (n = 6). (B) Stability of pre-miR-503 conjugated with polyamine-CNTs in
serum. Values are expressed as pre-miR-503 expression compared to pre-miR-503 values at time 0. Mean ± SEM (n = 6). (C) Influence of
PANAM-CNT-pre-miR-503 on vessel outgrowth from mouse aortic rings. **P b 0.01 vs CNT-control. Mean ± SEM (n = 6/group) and representative
microscopy images of vessels outgrowth from mouse aortic ring in the presence of PAMAM-CNT-control or PAMAM-CNT-pre-miR-503.
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Importantly, subcellular localization of CNTs depends on the
method by which CNTs enter the cell.41 Although the mechanism
of cellular uptake is still unclear, a common pathway for the
cellular uptake of functionalized CNTs is the active transport via
endocytosis and inclusion ofCNTs in vesicles or vacuoles.42 In our
study, the delivery of miRNA conjugated with polymer-coated
CNTs was first demonstrated by observing the fluorescence of
Cy-3 labelled miRNA using flow cytometry. Interestingly,
polyamine-CNTs-pre-miRNA formulations at 10:1 weight ratio
are able to transfect ECs with the same efficiency of Lipofecta-
mine. The good transfection efficiency of these systems is due to
the presence of PEI and PAMAM, two polymers with excellent
transfection properties.43-45 Another notable observation is that
PAMAM-CNTs showed a higher efficacy of transfection compared
with PEI-CNTs. We can speculate that the polyamide chemical
structure of PAMAM can optimize complexation with miRNAs,
therefore facilitating their subsequent release.We further characterized
the intracellular uptake of the PAMAM-CNTs-miRNA complex.
TEM images confirmed that the PAMAM-CNT-miRNA complex
was indeed inside the cells' cytoplasm, and, specifically, in vacuoles.Interestingly, the accumulation of autophagosomes in
cultured human umbilical vein endothelial cells (HUVECs)
treated with carboxylated multiwalled carbon nanotubes
(MWCNTs) has been observed,46 although our systems are
quite different. In any case, we cannot exclude that the
hydrophilic polymer-coated CNTs employed in this study
might insert spontaneously into the lipid bilayer47 or enter the
cell by passing through the membrane as “needles”. The uptake and
release of RNA-wrapped double-walled carbon nanotubes
(DWNTs) by cultured human cancer cells has been studied by
Neves et al who demonstrated that these nanotubes are visible within
endosomes just after 30 min after transfection and are completely
released by cells over a 24 h time period.48 In our experimental
conditions, using primary EC, we have shown that CNTs are still in
the cells after 48 h from transfection (Figure 3, B and C). However,
we would like to highlight that different cellular systems, in
particular cancer cells, have different internalization and release
mechanisms. Therefore, to unravel completely the mechanisms and
the kinetics of internalization and retention of our polyamine-coated
CNTs and to define which process is engaged to remove them from
cells, a more focused set of in vitro experiments are needed.
Figure 7. Delivery of PAMAM-CNTs-miR-503 reduces in vivo angiogenesis.(A) Expression of miR-503 or (B) CDC25A in sponges treated with pre-miR-503
conjugatedwith PAMAM-CNTs or control oligonucleotides. The expression of miR-503 andCDC25Awas normalized to snRU6 or 18S, respectively.Mean ± SEM
(n = 6). *P b 0.05 vs CNT-control.(C) Quantification of VE-cadherin/SM22 positive vessels in sponges treated with PAMAM-CNT-pre-miR-503 or
PAMAM-CNT-control at 21 days after implantation *P b 0.05 vs CNT-control. Mean ± SEM (n = 6/group). (C) Quantification of apoptosis (TUNEL assay) in
vessels in the same conditions reported above. Mean ± SEM (n = 6). (D) Representative images of the vessels positive for VE-cadherin (green fluorescence) and
SM22 (red fluorescence) in the implanted sponges (Magnification 400×; scale bar 100 μm).
1520 A. Masotti et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 1511–1522In recent years, efforts have been made to design and deliver
pharmacologically-active synthetic miRNAs and, specifically, to
produce oligonucleotides that bind to their miRNA targets with
remarkable affinity and specificity and have suitable drug-like
qualities (such as increased stability and pharmacokinetics).8Our data further show that PAMAM-CNTs complexed with
miR-503 precursors or inhibitors exhibited the best ratio of silencing
efficacy vs toxicity in ECs, achieving strong gene expression
regulation of the target gene CDC25A and in vitro angiogenesis.
Following these encouraging results, PAMAM-CNT-miR-503
1521A. Masotti et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 1511–1522complex was also administered locally using a sponge implant
mouse model. In our hands the sponge model is well adapted for
analysis of the effects of the PAMAM-CNT-miRNAs complex on
the stability and local release of miRNA oligonucleotides in vivo in a
model of angiogenesis. We found that the PAMAM-CNT-miR-503
formulation increased the stability ofmiR-503 oligonucleotides, thus
resulting in a prolonged silencing effect of its target gene CDC25A
and inhibition of angiogenesis after 21 days.
Taken together our data determined that the direct conjuga-
tion of CNTs with PEI or PAMAM polymers can afford effective
and stable carriers for miRNA delivery into ECs. We
demonstrated that polymer-coated CNTs can release miRNAs
and regulate cell proliferation and in vitro and in vivo
angiogenesis through the modulation of miRNA target gene
expression. In addition, our results demonstrated that the
nanostructured systems developed in this work display minimal
cytotoxicity, and are efficient non-viral vectors for the delivery
of miRNA-based oligonucleotides to ECs, thus making them
promising delivery vectors for cardiovascular applications.
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